Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome

Ann Hematol. 2021 Mar;100(3):837-839. doi: 10.1007/s00277-020-04291-0. Epub 2020 Oct 1.

Authors

Márcio Tavares¹, Sérgio Chacim², José Mário Mariz²

Affiliations

¹ Departamento de Onco-Hematologia, Instituto Português de Oncologia do Porto, Rua Dr. António Bernardino Almeida, 4200-072, Porto, Portugal. marcio.tavares@ipoporto.min-saude.pt.
² Departamento de Onco-Hematologia, Instituto Português de Oncologia do Porto, Rua Dr. António Bernardino Almeida, 4200-072, Porto, Portugal.

PMID: 33001280
DOI: 10.1007/s00277-020-04291-0

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Benzimidazoles / administration & dosage
Benzimidazoles / adverse effects
Compassionate Use Trials*
Cytarabine / administration & dosage
Cytarabine / adverse effects
Female
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / pathology
Male
Middle Aged
Myelodysplastic Syndromes / drug therapy*
Myelodysplastic Syndromes / pathology
Phenylurea Compounds / administration & dosage
Phenylurea Compounds / adverse effects

Substances

Benzimidazoles
Phenylurea Compounds
Cytarabine
glasdegib